中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.026 seconds)

    ESTROGEN RECEPTOR MODULATORS
    4.
    发明授权
    ESTROGEN RECEPTOR MODULATORS 有权
    雌激素受体调节剂

    公开(公告)号：EP1943224B1

    公开(公告)日：2011-07-27

    申请号：EP06849833.6

    申请日：2006-09-29

    Applicant: Merck Sharp & Dohme Corp.

    Inventor： GREENLEE, Mark, L. ,  MENG, Dongfang ,  PARKER, Dann, L., Jr. ,  SUN, Wanying ,  WILDONGER, Kenneth, J. ,  WILKENING, Robert, R.

    IPC: C07D231/00 ,  A61K31/416 ,  A61K31/4192 ,  C07D249/16

    CPC classification number: C07D249/16 ,  C07D231/54 ,  C07D235/02 ,  C07D405/04 ,  C07D413/04

    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.

    FACTOR IXA INHIBITORS
    5.
    发明公开
    FACTOR IXA INHIBITORS 审中-公开
    因子IXA抑制剂

    公开(公告)号：EP3229801A1

    公开(公告)日：2017-10-18

    申请号：EP15866965.5

    申请日：2015-12-07

    Applicant: Merck Sharp & Dohme Corp. ,  Mochida Pharmaceutical Co., Ltd.

    Inventor： ZHANG, Ting ,  CHEN, Yi-Heng ,  GUO, Liangqin ,  HRUZA, Alan ,  JIAN, Tianying ,  LI, Bing ,  MENG, Dongfang ,  PARKER, Dann, L., Jr. ,  SHERER, Edward, C. ,  WOOD, Harold, B. ,  SAKURADA, Isao

    IPC: A61K31/4184 ,  C07D235/04

    Abstract: The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

    Abstract translation: 本发明提供式I化合物和包含一种或多种所述化合物的药物组合物，以及使用所述化合物治疗或预防不稳定心绞痛，难治性心绞痛，心肌梗塞，短暂性脑缺血发作，心房纤颤，血栓性中风，栓塞 中风，深静脉血栓形成，弥散性血管内凝血，纤维蛋白的眼部积聚以及再通血管的再闭塞或再狭窄。 这些化合物是选择性因子IXa抑制剂。

    ANTIFUNGAL AGENTS
    7.
    发明公开
    ANTIFUNGAL AGENTS 有权
    抗真菌剂

    公开(公告)号：EP2326172A1

    公开(公告)日：2011-06-01

    申请号：EP09806944.6

    申请日：2009-08-07

    Applicant: Merck Sharp & Dohme Corp.

    Inventor： GREENLEE, Mark, L. ,  WILKENING, Robert ,  APGAR, James ,  WILDONGER, Kenneth, James ,  MENG, Dongfang ,  PARKER, Dann, L, Jr.

    IPC: A01N37/18

    CPC classification number: A01N43/653 ,  A61K31/4196 ,  C07J71/0005

    Abstract: Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (l,3)-
    β -D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating, and/or preventing fungal infections and associated diseases and conditions.

    Abstract translation: 本文公开了enfumafungin的新衍生物及其药学上可接受的盐，水合物和前药。 还公开了包含此类化合物的组合物，制备此类化合物的方法以及使用此类化合物作为抗真菌剂和/或（1,3）-β-D-葡聚糖合酶抑制剂的方法。 公开的化合物，其药学上可接受的盐，水合物和前药以及包含这些化合物，盐，水合物和前药的组合物可用于治疗和/或预防真菌感染和相关疾病和病症。

Patent Agency Ranking